Project Overview

mRNA and RNAi, among other micro-nucleic acid gene regulation mechanisms and their applications, represent the cutting-edge fields of biotechnology. The Disabled Friends Biotechnology Research Institute has leveraged existing resources to achieve localized research outcomes. In 2023, the institute will deepen and expand its efforts based on established technological foundations, introducing and learning new technologies to accumulate technical reserves for further breakthroughs in the field of biological disabilities.

Project Background

Among all biomedical technologies that may assist people with disabilities, RNA holds significant advantages. Whether it's RNA interference represented by miRNA or antisense oligonucleotides, these are technologies with the potential to ultimately reverse genetic defects. Additionally, miRNA and mRNA are key components of stem cell regeneration and repair technologies, such as paracrine mechanisms. Therefore, the Disabled Friends Biotechnology Research Institute has prioritized RNA technology as a breakthrough approach to transform the lives of people with disabilities and realize the dream of a disability-free world.

In 2020, the global microRNA market was valued at $8.0546 billion, with a projected compound annual growth rate (CAGR) of 19.8% from 2021 to 2028.
In 2023, the Disabled Friends Biotechnology Research Institute's RNA focus will primarily center on the following areas:
1. microRNA and related technologies in tumor and major chronic disease diagnostics, whether used independently or in combination with other techniques
2. microRNA and related technologies in disease treatment research, breakthroughs, and experimental attempts, whether used independently or in combination with other techniques
3. Latest advancements in microRNA sequencing technologies, including spatial omics, temporal omics, and transcriptomics related to RNA sequencing
5. Research, breakthroughs, and experimental attempts in microRNA preparation and delivery technologies
6. Machine learning applications for microRNA-related disease big data collection, predictive modeling (methods to improve sensitivity and NPV values), and synchronization with animal and pathological experimental procedures

Exosome-based rehabilitation drugs:

Develop clinical application methods based on the above, such as intranasal or aerosolized drug delivery, to enhance rehabilitation efficiency.

Long-term goals:

1. Stem cell drugs.

2. Stem cell exosome drugs.

3. Monoclonal antibody drugs utilizing stem cell microvesicle delivery methods

4. miRNA-based diagnostic reagents (IVD) for specific tumors

5. miRNA-based diagnostic reagents (IVD) for Parkinson's disease

6. miRNA-based diagnostic reagents (IVD) for liver cirrhosis

Aging marks the onset of disease; cellular lifespan determines human longevity, and aging can be intervened and treated. Through scientific assessment of aging, pharmaceutical interventions, cellular interventions, genetic interventions, and proactive health measures, healthy aging can be achieved, maintaining a state of being old yet vigorous and free from illness.

In 2023, building on the institute's research in microRNA anti-aging, further efforts will be made to deepen technological capabilities in stem cell and related technologies in this field.

In 2023, the Disabled Friends Biotechnology Research Institute's AI big data team will focus on the following directions: microRNA, mRNA, and tRNA-based cell signaling pathway regulation technologies related to cancer projects, such as metabolic micro-pathway regulation based on NF-κB and AMPK-mTOR signaling pathways, cancer prevention micro-pathway regulation based on PI3K-AKT signaling pathways, and the development of a liver cancer ultra-early screening panel based on specific MicroRNA biomarker derived from bioinformatics databases (miRBase, miRDB) and clinical data from Peking University Shenzhen Hospital and Southern University of Science and Technology.

Advancing biological detection:: Establishing joint detection laboratories with major research institutions, with primary applications including

1. ENOX2 protein detection: Detecting ENOX2 protein in serum for high-incidence cancers such as ovarian cancer, breast cancer, and non-small cell lung cancer, using protein expression levels to determine tumor progression

2. Circulating Tumor Cell (CTC) detection: CTC refers to tumor cells shed from primary or metastatic sites into the bloodstream. The institute employs DNA-FISH, droplet PCR, and other methods for detection, alongside CD45 staining to enhance specificity, enabling detection of high-incidence cancers such as lung cancer, colorectal cancer, and nasopharyngeal cancer with high accuracy.

Innovative protein detection technologies

Enhancing the sensitivity and specificity of protein detection technologies

Developing new antibodies or reagents to improve protein detection accuracy.

Optimizing experimental methods and conditions to enhance detection sensitivity.

Exploring novel protein detection methods

Developing new protein detection methods by integrating microfluidic chips, biosensors, and other technologies.

Validating new strategies and technologies in anti-aging research

Assessing the effectiveness of anti-aging strategies

Utilizing protein detection technologies to monitor the effects of anti-aging strategies

Project Objectives

By introducing and mastering biotechnology, the institute aims to enhance its technical capabilities, expand its technological system, and accumulate technical talent for further development. Clear positioning will be established for microRNA-related animal experiments and products, identifying microRNA associated with cellular aging and studying its regulatory mechanisms on cellular senescence.